Literature DB >> 27188665

Varicella zoster virus infection.

Anne A Gershon1, Judith Breuer2, Jeffrey I Cohen3, Randall J Cohrs4, Michael D Gershon5, Don Gilden4, Charles Grose6, Sophie Hambleton7, Peter G E Kennedy8, Michael N Oxman9, Jane F Seward10, Koichi Yamanishi11.   

Abstract

Infection with varicella zoster virus (VZV) causes varicella (chickenpox), which can be severe in immunocompromised individuals, infants and adults. Primary infection is followed by latency in ganglionic neurons. During this period, no virus particles are produced and no obvious neuronal damage occurs. Reactivation of the virus leads to virus replication, which causes zoster (shingles) in tissues innervated by the involved neurons, inflammation and cell death - a process that can lead to persistent radicular pain (postherpetic neuralgia). The pathogenesis of postherpetic neuralgia is unknown and it is difficult to treat. Furthermore, other zoster complications can develop, including myelitis, cranial nerve palsies, meningitis, stroke (vasculopathy), retinitis, and gastroenterological infections such as ulcers, pancreatitis and hepatitis. VZV is the only human herpesvirus for which highly effective vaccines are available. After varicella or vaccination, both wild-type and vaccine-type VZV establish latency, and long-term immunity to varicella develops. However, immunity does not protect against reactivation. Thus, two vaccines are used: one to prevent varicella and one to prevent zoster. In this Primer we discuss the pathogenesis, diagnosis, treatment, and prevention of VZV infections, with an emphasis on the molecular events that regulate these diseases. For an illustrated summary of this Primer, visit: http://go.nature.com/14xVI1.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 27188665      PMCID: PMC5381807          DOI: 10.1038/nrdp.2015.16

Source DB:  PubMed          Journal:  Nat Rev Dis Primers        ISSN: 2056-676X            Impact factor:   52.329


  206 in total

1.  Controlled trial of acyclovir for chickenpox evaluating time of initiation and duration of therapy and viral resistance.

Authors:  H H Balfour; C K Edelman; R S Anderson; N V Reed; R M Slivken; L H Marmor; L Dix; D Aeppli; C L Talarico
Journal:  Pediatr Infect Dis J       Date:  2001-10       Impact factor: 2.129

2.  Improved multiplex-PCR and microarray for herpesvirus detection from CSF.

Authors:  Anne J Jääskeläinen; Heli Piiparinen; Maija Lappalainen; Antti Vaheri
Journal:  J Clin Virol       Date:  2008-03-04       Impact factor: 3.168

3.  The prognosis with postherpetic neuralgia.

Authors:  Peter N C Watson; Verna R Watt; Mary Chipman; Nicholas Birkett; Ramon J Evans
Journal:  Pain       Date:  1991-08       Impact factor: 6.961

Review 4.  Neurological disease produced by varicella zoster virus reactivation without rash.

Authors:  Don Gilden; Randall J Cohrs; Ravi Mahalingam; Maria A Nagel
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

Review 5.  Varicella: historical perspective and clinical overview.

Authors:  T H Weller
Journal:  J Infect Dis       Date:  1996-11       Impact factor: 5.226

Review 6.  Aseptic meningitis and optic neuritis preceding varicella-zoster progressive outer retinal necrosis in a patient with AIDS.

Authors:  Carlos Franco-Paredes; Thomas Bellehemeur; Ali Merchant; Pramod Sanghi; Carlos DiazGranados; David Rimland
Journal:  AIDS       Date:  2002-05-03       Impact factor: 4.177

Review 7.  Meningoencephalomyelitis with vasculitis due to varicella zoster virus: a case report and review of the literature.

Authors:  Penelope A McKelvie; Steven Collins; Dominic Thyagarajan; Nicholas Trost; Harsha Sheorey; Edward Byrne
Journal:  Pathology       Date:  2002-02       Impact factor: 5.306

8.  Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox.

Authors:  M Brisson; N J Gay; W J Edmunds; N J Andrews
Journal:  Vaccine       Date:  2002-06-07       Impact factor: 3.641

9.  Risk of herpes zoster in children with leukemia: varicella vaccine compared with history of chickenpox.

Authors:  P A Brunell; J Taylor-Wiedeman; C F Geiser; L Frierson; E Lydick
Journal:  Pediatrics       Date:  1986-01       Impact factor: 7.124

10.  Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study.

Authors:  Elchonon M Berkowitz; Graeme Moyle; Hans-Jürgen Stellbrink; Dirk Schürmann; Stephen Kegg; Matthias Stoll; Mohamed El Idrissi; Lidia Oostvogels; Thomas C Heineman
Journal:  J Infect Dis       Date:  2014-11-03       Impact factor: 5.226

View more
  132 in total

Review 1.  The bowel and beyond: the enteric nervous system in neurological disorders.

Authors:  Meenakshi Rao; Michael D Gershon
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-07-20       Impact factor: 46.802

Review 2.  The alpha-herpesviridae in dermatology : Varicella zoster virus.

Authors:  L El Hayderi; A Rübben; A F Nikkels
Journal:  Hautarzt       Date:  2017-12       Impact factor: 0.751

Review 3.  [The alpha-herpesviridae in dermatology : Varicella zoster virus. German version].

Authors:  L El Hayderi; A Rübben; A F Nikkels
Journal:  Hautarzt       Date:  2017-03       Impact factor: 0.751

4.  Herpes Zoster Rates Continue to Decline in People Living With Human Immunodeficiency Virus but Remain Higher Than Rates Reported in the General US Population.

Authors:  Laura Gilbert; Xun Wang; Robert Deiss; Jason Okulicz; Ryan Maves; Christina Schofield; Tomas Ferguson; Timothy Whitman; Karl Kronmann; Brian Agan; Anuradha Ganesan
Journal:  Clin Infect Dis       Date:  2019-06-18       Impact factor: 9.079

5.  Varicella Vaccine: What Have You Done for Me Lately?

Authors:  Anne A Gershon
Journal:  Pediatrics       Date:  2019-06-10       Impact factor: 7.124

6.  THE JEREMIAH METZGER LECTURE VARICELLA ZOSTER VIRUS: FROM OUTSIDE TO INSIDE.

Authors:  Anne A Gershon; Michael D Gershon
Journal:  Trans Am Clin Climatol Assoc       Date:  2016

Review 7.  Human inborn errors of immunity to herpes viruses.

Authors:  Emmanuelle Jouanguy; Vivien Béziat; Trine H Mogensen; Jean-Laurent Casanova; Stuart G Tangye; Shen-Ying Zhang
Journal:  Curr Opin Immunol       Date:  2020-01-31       Impact factor: 7.486

Review 8.  The immunoinhibitory PD-1/PD-L1 pathway in inflammatory blood vessel disease.

Authors:  Cornelia M Weyand; Gerald J Berry; Jörg J Goronzy
Journal:  J Leukoc Biol       Date:  2017-12-29       Impact factor: 4.962

9.  Seroprevalence survey for Varicella among healthcare workers and medical students in Italy.

Authors:  Ottavia Balbi; Savino Baldi; Stefano Rizza; Antonio Pietroiusti; Stefano Perrone; Luca Coppeta
Journal:  Hum Vaccin Immunother       Date:  2020-07-09       Impact factor: 3.452

10.  Concerns on Vaccine against Varicella Caused by Varicella-Zoster Virus Infection.

Authors:  Wen-Bo Zeng; Fukun Zhang; Shuang Cheng; Jin-Yan Sun; Hongjie Shen; Min-Hua Luo
Journal:  Virol Sin       Date:  2020-05-28       Impact factor: 4.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.